An Open Label Study to Determine ADME of 14C Labeled SLV334 and Its Metabolites After Single Intravenous Dose Infusion.
Latest Information Update: 23 Sep 2010
At a glance
- Drugs SLV 334 (Primary)
- Indications Chronic brain damage
- Focus Pharmacokinetics
- 03 Apr 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 03 Apr 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 03 Apr 2010 Actual initiation date (Feb 2010) added as reported by ClinicalTrials.gov.